Explorative study for identifying factors to predict transition to schizophrenia in participants at Ultra High Risk for Psychosis by using bioinformation assessment and cytokine measurements.
- Conditions
- ltra high risk for psychosis
- Registration Number
- JPRN-UMIN000030693
- Lead Sponsor
- ational Center of Neurology and Psychiatry
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up continuing
- Sex
- All
- Target Recruitment
- 80
Not provided
1) Those who have neurological or medical conditions as below: atypical headache, history of head trauma with loss of consciousness, chronic pulmonary disease, kidney disease, chronic liver disease, thyroid disease, active cancer, cerebrovascular disease, epilepsy, neurological disorder, substance related disorder, or mental retardation(IQ<70), obvious history of psychosis. 2) Those who are not seeking for help. 3) Those who suffer from autoimmune disease(SLE, hyperthyroidism: Graves' disease, ulcerative colitis, Crohn's disease). 4) Regular use of steroid or NSAID. 5) The attending physician decided that the patient was inappropriate to participate in the study.
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method (a) sleep related information collected using actigraph Total sleep time(TST), sleep efficiency(SE), wake time after sleep onset(WASO), and sleep latency(SL) (b) positive symptoms SOPS(scale of prodromal symptoms) (c) Serum cytokine level, number of blood cells including white blood cell percentage, and CRP: IL-1beta, IL-6, TGF-beta, IL-12, IFN-gamma, TNF-alpha, and sIL-2R: serum level of pro-BDNF, mature-BDNF, and oxytocin, measured in the blood sample collected between 9:00am-10:00am.
- Secondary Outcome Measures
Name Time Method (a) Pittsburgh Sleep Quality Index(PSQ) (b) Specific Levels of Functioning Scale(SLOF) (c) Beck Depression Inventory-2(BDI-2) (d) Height, weight, smoking status